Jeff. our partnering us indications. thank sharpen and joining benefit will that our how on multiple We hope potential call, financing announced families you and enabled On I afternoon, and your Thanks, us. you Jen are across the maximizing of discuss for agreements well. everyone, have and patients recently Good today's to focus to trilaciclib
in for corporate beginning the prepared with Boehringer focus commercialization trilaciclib's potential the strategy three, shareholders. review we After to commercial development supporting trilaciclib, will continuing plans rintodestrant provide our To year, application of serve NDA; as remarks, a completing trilaciclib our first for we is the new the to beyond questions. report to strategy; value strategy, small Raj the goals. drug overview and delivered our cancer. our the support rintodestrant Ingelheim. to our and of with patients an that trial trila. to goals implementing that call evaluate of along lung infrastructure to of of on pleased XXXX to development we palbociclib; nondilutive will launch funding identifying advance and all on execute continued have outlined launch we'll the included: way combination end, partnership At and development or create on I'm launch are initiating cell robust today open four, of Soma also establishing the a one, medical how the trilaciclib comment and trila and team our two, best including those
filing in payments milestone as to U.S. the that combination completed in payments, initiated have closed plus bolstered the brought in $XX launch four and royalties in rinto/palbo of upfront NDA and trilaciclib trial the the June $XXX million up partnerships trila We scheduled. million We collectively strategic in
strengthened care to In resources million value a for companies expected our exposure capital, with our addition, value in critical $XXX this nondilutive to partnership; significant available access and to positioning several facility. our cash enabling continuing limited credit advance rintodestrant a that point and can lerociclib advance Moreover, flexible to sheet to to runway. have Collectively, of GX of where and most the we we health business value to focus and patients. and our which we've development partner including potential patients, and our balance deliver system on secured accomplishments to therapy realizing have expenses development inflection it make XXXX, the future meaningful with is of to trilaciclib, have commercialization the advance significantly the us these a enabled objectives, investors;
for we patients possible. small submitted therapy cell designation. of breakthrough as drug cancer. trilaciclib June And to is Last year, make available year, priority application in received highest to lung we this as quickly a Our new
any patients. with track based We launch, will potential as review would sales a PDUFA shared a vision expense several stakeholders announced We with and for us to derisks This options expect factors, later limits date. on month for launch of to our our approval for on assign submission our including outcome do optionality all trilaciclib it liability this by in component key explored of support. frame agreement is our XXXX. our maintained and decision critical put for A priority range a BI that initial a the during our first was attractive of time collaborate recently strategy agreement for quarter Boehringer lockup. co-promotion A FDA great respond a what could Ingelheim. this avoiding And the long-term is
working a with own can approach In than expertise addition scratch. the this ground with more of capital the much hit the that efficient our is sales from right partner benefits to team creating running,
that The end is element cell timing for the trials. with agreement this is X limited readouts the cancer lung indication. from key of the Another of colorectal agreement I-SPY to small the data a and coincides X-year support
time for While BI, additional with successful trilaciclib partnership frame launching we this forward a flexibility in us indications have that as populations. are larger to we provides patient with significantly looking evaluate options
trilaciclib, tumor plans discuss and excited patients to launch on Soma affairs outreach team's oncology comments provide strategy to Related on in U.S., practice for will Group prepare our development providers, Simcere partnership in unlock evaluate recently we to for about centers, benefit may announced with care payers, Raj trilaciclib provide Pharmaceuticals committees stakeholders. relevant in health successful significant and the our the our regimens China. including are a collaboration company. call. types commercial additional also and where and other color value Raj later guideline efforts also our our additional the will development chemo for medical will to
China. player in to clinical addition in Simcere and trilaciclib tumor trials experience we China, evaluating in their in In executing being benefiting commercial types collaborate look will to well-established trials a additional with forward from
ongoing as combination the future rintodestrant. being milligrams will XXX rintodestrant in to development dose began inhibitor, evaluate recruitment the Last our led provided palbociclib, is by we CDKX/X arm of under with quarter, a oral that the go-forward to an Phase our trial in agreement. us of nonexclusive supply trial trials. Turning which select Findings Pfizer for have from SERD I/II
Before comment relative a on to our I Soma, pandemic. turn call the brief seen date, interruptions significant operations the not any COVID-XX to our over have business. To we to
anticipate Soma discuss some on our delays. or initial we remain clinical to overall expect I chain commercial do our to call production would strategy for supply recruitment turn lines now While to impact Similarly, trial enrollment, on track. not over we like time the trilaciclib.
Soma?
